PRESS RELEASE
PITTSBURGH – Eclipse Screening Technologies, the company behind VeroVision Mail Screener+, today announced the appointment of Dr. Douglas Greene as its new Chief Medical Officer. A recognized leader in medical research and public health, Dr. Greene will guide Eclipse Screening Technologies’ efforts in developing advanced drug interdiction solutions that enhance safety for correctional staff and incarcerated individuals.
Dr. Greene brings extensive expertise in drug safety and drug regulation. He will work closely with correctional institutions and policymakers to address the growing crisis of illicit substances infiltrating prison systems. In his role, Dr. Greene will play a pivotal role in advancing research and collaborating with correctional agencies.
“Preventing the flow of dangerous substances into correctional facilities is a public health and safety imperative,” said Dr. Doug Greene. “I am excited to join Eclipse Screening Technologies and contribute to its mission of providing cutting-edge solutions that protect staff, incarcerated individuals, and communities.”
Dr. Greene has served as Chair of the Endocrinologic and Metabolic Drug Advisory Board for the U.S. Food and Drug Administration in Washington, D.C. He has also served in leadership roles at various pharmaceutical and drug development companies. He most recently served as the Founder and Chief Consultant of DAGPHAMED LLC.
“Bringing Dr. Greene onto our team reflects our continued commitment to innovation, research, and the development of evidence-based solutions to combat contraband in correctional settings,” said Pete Safran, Chief Executive Officer at Eclipse.
Dr. Greene earned his BA in Biology from Princeton University and his MD from the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency at Johns Hopkins Hospital, followed by a post-doctoral research fellowship at the Cox Research Institute at the University of Pennsylvania.
About Eclipse Screening Technologies LLC
Eclipse Screening Technologies LLC is a DEA-registered research facility whose mission is to identify and deter mail-borne threats. With installations nationwide, our disruptive contraband interdiction solutions, featuring the VeroVision Mail Screener and Mail Screener+, help corrections facilities keep staff and inmates safe. VeroVision Mail Screener+ is the only imaging-based technology to detect and presumptively identify drugs and cutting agents in mail items, including sprayed or soaked onto paper. Eclipse Screening Technologies is a wholly owned subsidiary of Eclipse Design Ventures. Corporate headquarters, sales, and service are based in Pittsburgh, PA. R&D and manufacturing are based in Salt Lake City, UT. Learn more at www.eclipse-st.com.